Refer a patient.

Have a patient with atopic dermatitis who may be interested in the ADvocate Studies?

The primary objective of the ADvocate Studies is to evaluate the safety and efficacy of lebrikizumab compared to placebo in patients with moderate to severe AD.

Who is eligible?

Eligible patients must:

  • Be male or female, 12 years of age or older
  • Weigh at least 40 kg (88 lb.)
  • Have chronic atopic dermatitis for at least one year prior to the screening visit
  • Have a history of inadequate response to treatment with topical medications or a determination that topical treatments are otherwise medically inadvisable

ADvocate Studies research sites.

If you have a patient who may be interested in participating, and you think may qualify, refer your patient to this website to take the prescreening questionnaire to determine eligibility, or fill out a contact request form if you would like to request contact directly from an active research site.

Find the site nearest you.

Enter your zip code below or click on the map to find the participating research site(s) nearest you.

View full list of sites.

Active site locations Future site locations